Clinical Trials for Pancreas Cancer

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with histologically confirmed pancreatic ductal adenocarcinoma and nominal oligometastatic disease (1–5 lesions), ECOG 0–2, eligible for definitive local therapy to all sites, are randomized to standard systemic therapy alone versus systemic therapy plus comprehensive metastasis-directed therapy (e.g., SBRT/external-beam RT, surgery, ablation, or embolization to all known sites, including the primary). Suitable for patients without malignant effusions/peritoneal carcinomatosis and with recent imaging confirming oligometastatic status; prior induction to oligometastatic state allowed if sustained ≥6 months.

ClinicalTrials.gov ID: NCT06593431

Phase 2 Randomized Trial of Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Pancreatic Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with histologically confirmed oligometastatic pancreatic adenocarcinoma (≤5 extracranial metastases, all SBRT-amenable; ECOG 0–2) are randomized to standard metastatic chemotherapy (e.g., FOLFIRINOX or gemcitabine-based) with or without SBRT to all metastatic sites. Crossover to SBRT is allowed for local progression without new metastases; outcomes include PFS, response, OS, and safety.

ClinicalTrials.gov ID: NCT04975516

A Phase II Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR2 Gene Fusions or Other FGFR Genetic Alterations

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with advanced/metastatic pancreatic cancer harboring FGFR alterations receive oral pemigatinib (FGFR1–3 tyrosine kinase inhibitor) in 21‑day cycles; Cohort 1 requires FGFR2 fusion/translocation and KRAS-wild type, while Cohort 2 includes other activating FGFR1/2/3/4 alterations (KRAS co-mutations allowed), all after progression/intolerance to standard therapy and no prior FGFR inhibitor. Single-arm telemedicine study assessing response, PFS, and safety, with attention to class‑typical toxicities (e.g., hyperphosphatemia, ocular events).

ClinicalTrials.gov ID: NCT06906562

A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with well-differentiated (G1–2), SSTR-positive pancreatic NETs that are unresectable/metastatic and have progressed after ≥1 prior systemic therapy (no prior PRRT or fulvestrant) receive 177Lu-DOTATATE plus fulvestrant. Fulvestrant, a selective estrogen receptor degrader with potential radiosensitizing effects, is combined with standard PRRT to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06663072

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma (ECOG 0–2) without prior pancreatic radiation receive stereotactic-like adaptive radiation therapy in 5 every-other-day fractions after optional induction chemotherapy. The trial escalates ART dose to biologically aggressive tumor regions while sparing organs-at-risk, with primary focus on grade ≥3 GI toxicity and secondary measures of local control and survival.

ClinicalTrials.gov ID: NCT06984562

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma who have disease control after 4–6 months of first-line chemotherapy (FOLFIRINOX/mFOLFIRINOX, NALIRIFOX, or gemcitabine/nab-paclitaxel) are randomized to standard post-induction management (continue chemo, standard-dose chemoradiation with 5-FU/capecitabine, or observation) versus dose‑escalated radiation (preferably 5 fractions; or 25 fractions with optional 5-FU/capecitabine), with chemotherapy completion to 6 months as needed. No investigational drugs are used; the trial tests whether higher-dose, precision RT improves survival.

ClinicalTrials.gov ID: NCT06958328

A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with metastatic PDAC and cancer-associated cachexia (ECOG 0–1) beginning next cycle of first-line nab-paclitaxel/gemcitabine or (m)FOLFIRINOX are randomized to add ponsegromab, a subcutaneous anti–GDF-15 monoclonal antibody aimed at improving appetite/weight and function, versus placebo. Investigational therapy is given Q4W alongside standard chemotherapy; exclusions include reversible anorexia causes, CNS metastases, significant cardiac dysfunction, severe hepatic/renal impairment, and tube or parenteral feeding.

ClinicalTrials.gov ID: NCT06989437

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: Eligible patients are adults with select advanced or metastatic solid tumors (including colorectal, cholangiocarcinoma, appendiceal, pancreatic, gastric, endometrial, triple negative breast, ovarian, or prostate cancers) who have exhausted standard therapies; phase 2 focuses on colorectal cancer. Therapy is with APL-5125, an oral CK2α kinase inhibitor targeting Wnt signaling.

ClinicalTrials.gov ID: NCT06399757

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS G12C mutations (including pretreated NSCLC and other solid tumors), who receive a combination of the investigational KRAS G12C inhibitors RMC-6291 and RMC-6236. Both agents specifically inhibit KRAS G12C mutant protein to suppress tumor growth, and eligibility includes both KRAS G12C inhibitor–naïve and previously treated patients, excluding those with primary CNS tumors or active brain metastases.

ClinicalTrials.gov ID: NCT06128551

A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced solid tumors who have exhausted standard treatment options, testing the investigational single-agent ACTM-838 (mechanism of action not specified) as monotherapy. Eligible patients must have measurable disease, good performance status, adequate organ function, and CD4 counts >500/mL.

ClinicalTrials.gov ID: NCT06336148